10x Genomics (TXG) Non-Current Deffered Revenue (2018 - 2026)

10x Genomics has reported Non-Current Deffered Revenue for 7 years, with the latest figure at $10.1 million in Q1 2026.

• Quarterly Non-Current Deffered Revenue fell 19.34% year-over-year to $10.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.1 million (down 19.34% YoY) and the FY2025 annual result came in at $10.5 million, down 16.08% from the prior year.
• Non-Current Deffered Revenue fell to $10.1 million in Q1 2026 per TXG's latest filing, from $10.5 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $12.6 million in Q1 2025 and troughed at $3.2 million in Q4 2022.
• A 5-year average of $10.3 million and a median of $10.9 million in 2025 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2023 and 2026: Non-Current Deffered Revenue surged 178.48% in 2023, then fell 19.34% in 2026.
• Over 5 years, Non-Current Deffered Revenue stood at $3.2 million in 2022, then soared by 178.48% to $8.8 million in 2023, then jumped by 41.97% to $12.5 million in 2024, then slipped by 16.08% to $10.5 million in 2025, then dropped by 3.46% to $10.1 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $10.1 million, $10.5 million, and $10.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.